This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Surgical Oncology  • Prognosis/ Outcomes  • Hepatobiliary Surgery  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

Philip D. Schneider, MD, PhD
Sacramento, Calif

Arch Surg. 2001;136:955.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This article is clearly and carefully presented in exquisite detail. The authors have succinctly shown that there are occasional patients who benefit from an aggressive approach to stage IV melanoma owing to metastatic disease isolated to the liver. This article must be carefully read to understand how meticulously these patients were selected. Although 5-year disease-free survival and overall survival was 12% and 29% in the group undergoing resection, this represents only 0.3% of the 1750 patients who were evaluated and found to have hepatic metastasis and 18% of those going through a rigorous screening process and thought to be potential resection candidates. It is also important at this time, when the technical capability of performing percutaneous liver ablation exists, to note that 30% of patients were excluded by findings noted only at the time of laparotomy.

The authors are to be commended for their careful . . . [Full Text of this Article]

RELATED ARTICLE

Surgical Resection for Metastatic Melanoma to the Liver: The John Wayne Cancer Institute and Sydney Melanoma Unit Experience
D. Michael Rose, Richard Essner, T. Michael D. Hughes, Paul C. Y. Tang, Anton Bilchik, Leslie A. Wanek, John F. Thompson, and Donald L. Morton
Arch Surg. 2001;136(8):950-955.
ABSTRACT | FULL TEXT